243 related articles for article (PubMed ID: 23572427)
21. Rituximab for Inflammatory Myopathies in a Colombian Cohort.
Santos VA; Aragón CC; Posso-Osorio I; Naranjo-Escobar J; Milisenda JC; Obando MA; Barrera T; Zamorano L; Hormaza-Jaramillo A
J Clin Rheumatol; 2021 Sep; 27(6S):S232-S235. PubMed ID: 33337818
[TBL] [Abstract][Full Text] [Related]
22. Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy.
Lerario A; Cogiamanian F; Marchesi C; Belicchi M; Bresolin N; Porretti L; Torrente Y
BMC Musculoskelet Disord; 2010 Jul; 11():157. PubMed ID: 20618995
[TBL] [Abstract][Full Text] [Related]
23. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.
Valiyil R; Casciola-Rosen L; Hong G; Mammen A; Christopher-Stine L
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1328-34. PubMed ID: 20506493
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.
Campochiaro C; Farina N; De Luca G; Batani V; Trignani G; Vignale D; Palmisano A; Matucci-Cerinic M; Dagna L
Arthritis Res Ther; 2024 Apr; 26(1):79. PubMed ID: 38570792
[TBL] [Abstract][Full Text] [Related]
25. [Classification of idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific antibodies].
Zheng S; Chen S; Wu L; Zhao D; Chen F; Zhu J; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Jul; 40(7):1029-1035. PubMed ID: 32895158
[TBL] [Abstract][Full Text] [Related]
26. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.
Wilkes MR; Sereika SM; Fertig N; Lucas MR; Oddis CV
Arthritis Rheum; 2005 Aug; 52(8):2439-46. PubMed ID: 16052580
[TBL] [Abstract][Full Text] [Related]
27. Comparison of rituximab efficacy in treatment-naive and refractory inflammatory myopathies: experiences from a tertiary care centre.
Manwatkar A; Naresh K; Mathew J; Nair AV; Goel R; Yadav B; Prakash JAJ; Das JK; Sivadasan A
Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38814804
[TBL] [Abstract][Full Text] [Related]
28. Rituximab treatment in patients with refractory inflammatory myopathies.
Mahler EA; Blom M; Voermans NC; van Engelen BG; van Riel PL; Vonk MC
Rheumatology (Oxford); 2011 Dec; 50(12):2206-13. PubMed ID: 21571768
[TBL] [Abstract][Full Text] [Related]
29. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C
J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419
[TBL] [Abstract][Full Text] [Related]
30. Classification, diagnosis, and management of idiopathic inflammatory myopathies.
Lazarou IN; Guerne PA
J Rheumatol; 2013 May; 40(5):550-64. PubMed ID: 23504386
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Huang J; Du J; Wang S; Xiao L; Zhao X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
[TBL] [Abstract][Full Text] [Related]
32. Idiopathic inflammatory myopathies: a review.
Ashton C; Paramalingam S; Stevenson B; Brusch A; Needham M
Intern Med J; 2021 Jun; 51(6):845-852. PubMed ID: 34155760
[TBL] [Abstract][Full Text] [Related]
33. [Myositis-specific autoantibodies].
Gran JT; Molberg Ø; Dobloug GC; Andersson H; Taraldsrud E; Scheie D
Tidsskr Nor Laegeforen; 2009 Aug; 129(16):1631-4. PubMed ID: 19721478
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive insight into human aminoacyl-tRNA synthetases as autoantigens in idiopathic inflammatory myopathies.
Jura M; Rychlewski L; Barciszewski J
Crit Rev Immunol; 2007; 27(6):559-72. PubMed ID: 18197801
[TBL] [Abstract][Full Text] [Related]
35. [Clinical significance of magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults].
Nishikai M; Akiya K
Ryumachi; 2000 Dec; 40(6):881-90. PubMed ID: 11210772
[TBL] [Abstract][Full Text] [Related]
36. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
37. [Long-term rituximab treatment of refractory idiopathic inflammatory myopathy: A report of 3 cases].
Yi WX; Wei CJ; Wu Y; Bao XH; Xiong H; Chang XZ
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1191-1195. PubMed ID: 34916704
[TBL] [Abstract][Full Text] [Related]
38. Distinctive features of idiopathic inflammatory myopathies in French Canadians.
Uthman I; Vázquez-Abad D; Senécal JL
Semin Arthritis Rheum; 1996 Aug; 26(1):447-58. PubMed ID: 8870112
[TBL] [Abstract][Full Text] [Related]
39. Integrated Diagnosis Project for Inflammatory Myopathies: An association between autoantibodies and muscle pathology.
Suzuki S; Uruha A; Suzuki N; Nishino I
Autoimmun Rev; 2017 Jul; 16(7):693-700. PubMed ID: 28479486
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy.
Sultan SM; Ng KP; Edwards JC; Isenberg DA; Cambridge G
Clin Exp Rheumatol; 2008; 26(5):887-93. PubMed ID: 19032824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
